GVHD

Immunology

16 drugs in development·8 companies·5 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Niktimvo	Syndax Pharmaceuticals Inc (SNDX)

Phase 3(10)

Drug	Company
extracorporeal photopheresis	Incyte Corp. (INCY)
imatinib	Incyte Corp. (INCY)
infliximab	Incyte Corp. (INCY)
itacitinib	Incyte Corp. (INCY)
mechanistic target of rapamycin inhibitors	Incyte Corp. (INCY)
mycophenolate mofetil	Incyte Corp. (INCY)
pentostatin	Incyte Corp. (INCY)
plx-pad	Pluri Inc. (PLUR)
remestemcel-l-rknd	Mesoblast Limited (MESO)
tacrolimus	Incyte Corp. (INCY)

Phase 2(2)

Drug	Company
rls-0071	CV Sciences, Inc. (CVSI)
Vorinostat	Filana Therapeutics Inc. (FLNA)

Phase 1(1)

Drug	Company
amt-126	Applied Molecular Transport Inc. (AMTI)

BLA Filed(1)

Drug	Company
belumosudil	Kadmon Holdings, Inc. (KDMN)

Phase 4(1)

Drug	Company
ibrutinib	Incyte Corp. (INCY)

BioSniper tracks 16 drugs in development for GVHD across 8 companies.

There are 5 clinical trials targeting GVHD tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.